PDC*line Pharma seeks to go public in Korea Belgian-French clinical-stage biotech firm to become first European company listed here
Translated by Kim So-in 공개 2022-05-23 08:08:14
이 기사는 2022년 05월 23일 08:06 thebell 에 표출된 기사입니다.
PDC*line Pharma is seeking to go public in South Korea next year to become the first European company to list its shares here.Founded in 2014 as a spin-off from the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of plasmacytoid dendritic cells (PDC*line).
The company aims to go public in Korea next year, according to industry sources on Friday. There are two overseas companies listed on the country’s main bourse Kospi and 21 on the junior Kosdaq market, according to Korea Exchange.
Most recently, U.S.-based NeoImmuneTech and Singapore-based Prestige Biopharma made there market debuts here.
All foreign biotech firms listed on the domestic stock market are their Korean subsidiaries. They all collaborated with domestic personnel during their listing processes. In PDC*line Pharma’s case, the Belgian-French biotech company itself is going public.
The company has hired Mirae Asset Securities to handle the IPO process. PDC*line Pharma is considering to carry out its listing via the country’s special track like other domestic biotech firms did.
PDC*line Pharma completed its Series B2 round of financing in December 2021, raising a total of €17.5 million (23 billion won) from Belgian and South Korean investors.
The financing round was led by Korea Investment Partners and involved a syndicate of new South Korean investors in life sciences: Alpha Holdings, Brain Asset Management and Hansong Neotech.
Existing investors also participated: Noshaq Group, Sambrinvest, SFPI-FPIM (the Belgian Federal Holding and Investment Company) and SRIW (The Regional Investment Company of Wallonia). The proceeds will primarily be used to fund company’s phase I/II trial with PDC*lung01, a vaccine candidate for lung cancer. (Reporting by Joon-woo Nam)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
- 피디씨라인파마, 유럽기업 최초 '한국 상장' 도전
- Korean biotech startups wary of investing in IL-2 development
- Daewoong Pharmaceutical establishes first investment entity in U.S.
- HK Inno.N out-licenses GERD drug K-CAB to US pharma company
- GS Group accelerates investments in healthcare and pharma
- Huons BioPharma attracts $132 mil from China's Imeik Technology Development
best clicks
최신뉴스 in 전체기사
-
- 우리금융 "롯데손보 M&A, 과도한 가격 부담 안한다"
- 신한캐피탈, 지속성장 포트폴리오 리밸런싱 체계 강화
- 하나금융, ELS 악재에도 실적 선방…확고한 수익 기반
- 하나금융, 자본비율 하락에도 주주환원 강화 의지
- 국민연금, '역대 최대 1.5조' 출자사업 닻 올렸다
- [도전 직면한 하이브 멀티레이블]하이브, 강한 자율성 보장 '양날의 검' 됐나
- [퍼포먼스&스톡]꺾여버린 기세에…포스코홀딩스, '자사주 소각' 카드 재소환
- [퍼포먼스&스톡]LG엔솔 예견된 실적·주가 하락, 비용 절감 '집중'
- [퍼포먼스&스톡]포스코인터, 컨센서스 웃돌았지만 주가는 '주춤'
- 신한금융, ‘리딩금융’ 재탈환에 주주환원 강화 자신감